- Home
- EPOW vs ATNM Comparison
EPOW vs ATNM Comparison
Compare EPOW & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPOW | ATNM |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 50.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | EPOW | ATNM |
|---|---|---|
| Price | $0.96 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 249.6K | 224.5K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $64,997,741.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $42,943.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 44.28 | 11.11 |
| 52 Week Low | $0.73 | $1.03 |
| 52 Week High | $1.86 | $2.41 |
Technical Indicators
Market Signals| Indicator | EPOW | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 59.46 |
| Support Level | $1.00 | $1.37 |
| Resistance Level | $1.41 | $1.54 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 7.82 | 82.35 |
Price Performance
Historical ComparisonAbout EPOW Sunrise New Energy Co. Ltd
Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.